These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38344875)

  • 1. Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis.
    Bhatnagar S; Eckert D; Stodtmann S; Song IH; Wung P; Liu W; Mohamed MF
    Clin Transl Sci; 2024 Feb; 17(2):e13733. PubMed ID: 38344875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
    Fukui S; Kawaai S; Sawada H; Kishimoto M
    Expert Rev Clin Immunol; 2024 Feb; 20(2):141-153. PubMed ID: 37955181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
    Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
    Braun J; Kiltz U; Baraliakos X
    Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Deodhar A; Van den Bosch F; Poddubnyy D; Maksymowych WP; van der Heijde D; Kim TH; Kishimoto M; Blanco R; Duan Y; Li Y; Pangan AL; Wung P; Song IH
    Lancet; 2022 Jul; 400(10349):369-379. PubMed ID: 35908570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
    Malaviya AN; Kalyani A; Rawat R; Gogia SB
    Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
    van der Heijde D; Song IH; Pangan AL; Deodhar A; van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Everding A; Sui Y; Wang X; Chu AD; Sieper J
    Lancet; 2019 Dec; 394(10214):2108-2117. PubMed ID: 31732180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
    Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A
    Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
    van der Heijde D; Deodhar A; Baraliakos X; Brown MA; Dobashi H; Dougados M; Elewaut D; Ellis AM; Fleurinck C; Gaffney K; Gensler LS; Haroon N; Magrey M; Maksymowych WP; Marten A; Massow U; Oortgiesen M; Poddubnyy D; Rudwaleit M; Shepherd-Smith J; Tomita T; Van den Bosch F; Vaux T; Xu H
    Ann Rheum Dis; 2023 Apr; 82(4):515-526. PubMed ID: 36649967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
    van der Horst-Bruinsma IE; de Vlam K; Walsh JA; Bolce R; Hunter T; Sandoval D; Zhu D; Geneus V; Soriano ER; Magrey M
    Adv Ther; 2022 Jun; 39(6):2806-2819. PubMed ID: 35429281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
    Baraliakos X; Deodhar A; van der Heijde D; Magrey M; Maksymowych WP; Tomita T; Xu H; Massow U; Fleurinck C; Ellis AM; Vaux T; Shepherd-Smith J; Marten A; Gensler LS
    Ann Rheum Dis; 2024 Jan; 83(2):199-213. PubMed ID: 37793792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
    Ortolan A; Webers C; Sepriano A; Falzon L; Baraliakos X; Landewé RB; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):142-152. PubMed ID: 36261247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial.
    Van den Bosch F; Deodhar A; Poddubnyy D; Maksymowych WP; van der Heijde D; Kim TH; Kishimoto M; Baraliakos X; Li Y; D'Silva K; Wung P; Song IH
    ACR Open Rheumatol; 2024 Aug; 6(8):470-480. PubMed ID: 38747163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?
    Akkoc N; Khan MA
    Curr Rheumatol Rep; 2021 Apr; 23(6):34. PubMed ID: 33909185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
    Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Upadacitinib for Axial Spondyloarthritis: A Systematic Review and Meta-Analysis.
    Ali AHG; Elganady A; Hindawi MD; Mousa AIA; Eldeeb HA; Fatiem AR; Skopina Y
    Curr Rheumatol Rev; 2024 Aug; ():. PubMed ID: 39162272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension.
    van der Heijde D; Deodhar A; Maksymowych WP; Sieper J; Van den Bosch F; Kim TH; Kishimoto M; Östör AJ; Combe B; Sui Y; Duan Y; Wung PK; Song IH
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35896281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
    Sieper J; van der Heijde D; Dougados M; Mease PJ; Maksymowych WP; Brown MA; Arora V; Pangan AL
    Ann Rheum Dis; 2013 Jun; 72(6):815-22. PubMed ID: 22772328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.